Oxlumo Side Effects
Generic name: lumasiran
Medically reviewed by Drugs.com. Last updated on May 4, 2024.
Note: This document provides detailed information about Oxlumo Side Effects associated with lumasiran. Some dosage forms listed on this page may not apply specifically to the brand name Oxlumo.
Applies to lumasiran: subcutaneous solution.
Common side effects of Oxlumo
Some side effects of lumasiran may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common side effects
Serious side effects of Oxlumo
Along with its needed effects, lumasiran (the active ingredient contained in Oxlumo) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
For healthcare professionals
Applies to lumasiran: subcutaneous solution.
General adverse events
The most common side effect reported was injection site reactions.[Ref]
Gastrointestinal
- Very common (10% or more): Abdominal pain (included abdominal pain, upper abdominal pain, lower abdominal pain, abdominal discomfort, abdominal tenderness; up to 15%)[Ref]
Immunologic
- Common (1% to 10%): Anti-drug antibodies[Ref]
Anti-drug antibody titers were low and generally transient. No clinically significant differences in efficacy, safety, pharmacokinetic, or pharmacodynamic profiles of this drug were observed in patients who tested positive for anti-drug antibodies.[Ref]
Local
- Very common (10% or more): Injection site reaction (included injection site reaction, injection site erythema, injection site pain, injection site pruritus, injection site swelling, injection site discomfort, injection site discoloration, injection site mass, injection site induration, injection site rash, injection site bruising, injection site hematoma, injection site exfoliation; up to 38%)[Ref]
During clinical studies, injection site reactions occurred in 10% of injections. The most commonly reported symptoms included erythema, pain, pruritus, and swelling. Injection site reactions were generally mild, resolved within 2 days, and did not lead to interruption/discontinuation of therapy.[Ref]
References
1. (2021) "Product Information. Oxlumo (lumasiran)." Alnylam UK Ltd
2. (2022) "Product Information. Oxlumo (lumasiran)." Alnylam Pharmaceuticals
3. EMEA. European Medicines Agency (2007) EPARs. European Union Public Assessment Reports. http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid
4. (2020) "Product Information. Oxlumo (lumasiran)." Alnylam Pharmaceuticals
More about Oxlumo (lumasiran)
- Compare alternatives
- Pricing & coupons
- Drug images
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous metabolic agents
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Oxlumo side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.